Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Alumis Inc. (NASDAQ:ALMS) has earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $40.30.

Several equities analysts have commented on the stock. Raymond James Financial assumed coverage on shares of Alumis in a research note on Tuesday, March 10th. They issued a “strong-buy” rating and a $46.00 price target for the company. Wall Street Zen downgraded shares of Alumis from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Chardan Capital boosted their price target on shares of Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, May 19th. Morgan Stanley reaffirmed an “overweight” rating and set a $39.00 price objective on shares of Alumis in a research report on Friday, May 15th. Finally, Oppenheimer lifted their price objective on shares of Alumis from $50.00 to $55.00 and gave the stock an “outperform” rating in a research report on Monday, March 30th.

Institutional Investors Weigh In On Alumis

A number of institutional investors and hedge funds have recently bought and sold shares of ALMS. Russell Investments Group Ltd. lifted its position in Alumis by 320.9% in the third quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after acquiring an additional 4,894 shares during the last quarter. New York State Common Retirement Fund lifted its position in Alumis by 173.7% in the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after acquiring an additional 7,467 shares during the last quarter. KBC Group NV purchased a new stake in Alumis in the first quarter valued at $42,000. Strs Ohio lifted its position in Alumis by 300.0% in the first quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Alumis by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after acquiring an additional 979 shares during the last quarter.

Alumis Price Performance

Shares of NASDAQ ALMS opened at $23.00 on Tuesday. The company has a 50 day simple moving average of $22.84 and a 200-day simple moving average of $21.39. The company has a market capitalization of $2.93 billion, a P/E ratio of -11.62 and a beta of -0.55. Alumis has a 1 year low of $2.76 and a 1 year high of $30.60.

Alumis (NASDAQ:ALMS) last announced its earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The firm had revenue of $1.74 million during the quarter, compared to analysts’ expectations of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. As a group, research analysts expect that Alumis will post -2.87 EPS for the current year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.